Neurothera Labs Inc.
NTLX.V
TSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -22.82% | -9.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -22.82% | -9.23% | |||
| Cost of Revenue | -84.26% | -23.08% | |||
| Gross Profit | 176.64% | -1.78% | |||
| SG&A Expenses | 154.75% | -23.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.76% | -23.08% | |||
| Operating Income | -15.08% | 44.38% | |||
| Income Before Tax | -17.55% | 44.38% | |||
| Income Tax Expenses | 280.00% | -- | |||
| Earnings from Continuing Operations | -17.92% | 44.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -79.75% | -- | |||
| Net Income | -68.44% | 44.38% | |||
| EBIT | -15.08% | 44.38% | |||
| EBITDA | -17.74% | 40.49% | |||
| EPS Basic | -25.69% | -- | |||
| Normalized Basic EPS | -1,047.83% | -- | |||
| EPS Diluted | -25.69% | -- | |||
| Normalized Diluted EPS | -1,047.83% | -- | |||
| Average Basic Shares Outstanding | 34.12% | -- | |||
| Average Diluted Shares Outstanding | 34.12% | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||